allogeneic MSC - Cell La Vie

22ОктОктябрь 22, 2026

MSC Therapy for Alzheimer’s Disease: Clinical Trial Data on Laromestrocel and Biomarker Outcomes

Recent Phase 2a clinical trials demonstrate that mesenchymal stem cell therapy can slow brain atrophy by up to 62% and reduce neuroinflammation in mild Alzheimer's patients. Review of laromestrocel trial data, biomarker outcomes, and emerging treatment options.

болезнь Альцгеймера, МСК, Стволовые клеткиallogeneic MSC, MSC immunomodulation, терапия МСК, МСК, регенеративная медицина, стволовая клетка, стволовые клетки

21ОктОктябрь 21, 2026

MSC Therapy for Systemic Sclerosis: iPSC-Derived Stem Cells, Clinical Trials, and the Vasculopathy-Fibrosis Mechanism

A comprehensive 2026 review of mesenchymal stem cell therapy for systemic sclerosis (scleroderma), covering iPSC-derived MSCs, refrigerated cell delivery, blood vessel organoid models, and the MANUS clinical trial for digital ulcers.

МСК, Стволовые клеткиallogeneic MSC, autoimmune disease, иммунная система, мезенхимальный, MSC immunomodulation, терапия МСК, МСК, регенеративная медицина, стволовая клетка, стволовые клетки

15ОктОктябрь 15, 2026

MSC Therapy for Pediatric Acute GvHD: From FDA Approval to Next-Generation Approaches

The first FDA-approved MSC therapy (Ryoncil) ended a 20-year drought for cell-based products in the US. New real-world data from 139 children and next-generation platforms are reshaping how clinicians treat steroid-refractory pediatric GvHD.

МСК, Стволовые клеткиallogeneic MSC, иммунная система, МСК, регенеративная медицина, стволовая клетка, стволовые клетки